Leader Heartburn Relief and Ribociclib and Letrozole
Determining the interaction of Leader Heartburn Relief and Ribociclib and Letrozole and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Cimetidine may significantly increase the blood levels of ribociclib. You may be more likely to experience side effects such as nausea; vomiting; diarrhea; loss of appetite; mouth sores; abdominal pain, hair loss; weakness; headache; and impaired bone marrow function which can increase the risk of anemia, bleeding problems, and infections. Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact, or you may need a dose adjustment or more frequent monitoring to safely use both medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:MONITOR: Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations and risk of adverse effects of ribociclib, which is a substrate of the isoenzyme. Administration of erythromycin, a moderate CYP450 3A4 inhibitor, is predicted to increase ribociclib Cmax and AUC by 1.3- and 1.9-fold, respectively. Data with other, less potent inhibitors, are limited.
MANAGEMENT: Caution is advised when ribociclib is used with CYP450 3A4 inhibitors. Dosage adjustment for ribociclib is not generally considered necessary for suspected interactions with mild to moderate inhibitors. However, some manufacturers of ribociclib recommend that concomitant use with moderate CYP450 3A4 inhibitor verapamil should be avoided (AU, UK). Patients should be monitored for the development of ribociclib-related adverse effects such as infections, neutropenia, leucopenia, anemia, thrombocytopenia, nausea, vomiting, diarrhea, stomatitis, anorexia, alopecia, fatigue, headache, and abnormal liver function.
- "Product Information. Kisqali (ribociclib)." Novartis Pharmaceuticals, East Hanover, NJ.
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
- Cerner Multum, Inc. "Australian Product Information." O 0
Generic Name: cimetidine
Brand name: Tagamet HB, Tagamet
Synonyms: n.a.
Generic Name: letrozole / ribociclib
Brand name: Kisqali Femara Co-Pack 200 mg-25 mg Dose, Kisqali Femara Co-Pack 400 mg-25 mg Dose, Kisqali Femara Co-Pack 600 mg-25 mg Dose
Synonyms: Letrozole and ribociclib
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Leader Heartburn Relief-Ribociclib Succinate
- Leader Heartburn Relief-Rid-A-Pain Topical
- Leader Heartburn Relief-Ridactate
- Leader Heartburn Relief-Ridaura
- Leader Heartburn Relief-Rifabutin
- Leader Heartburn Relief-Rifadin
- Ribociclib and Letrozole-Leader Nicotine Polacrilex gum, lozenge
- Ribociclib and Letrozole-Leader Sleep Aid
- Ribociclib and Letrozole-Ledipasvir and sofosbuvir
- Ribociclib and Letrozole-Ledipasvir and Sofosbuvir Tablets
- Ribociclib and Letrozole-Leena
- Ribociclib and Letrozole-Lefamulin